Loading...
XMAD
FAE
Market cap1.74bUSD
Dec 04, Last price  
4.79EUR
1D
0.00%
1Q
11.14%
Jan 2017
42.56%
Name

Faes Farma SA

Chart & Performance

D1W1MN
XMAD:FAE chart
P/E
13.39
P/S
3.02
EPS
0.36
Div Yield, %
3.24%
Shrs. gr., 5y
2.51%
Rev. gr., 5y
6.67%
Revenues
494m
+9.42%
166,449,000185,187,000185,940,000194,180,000131,406,000202,507,000190,224,000176,109,000180,394,000191,742,000204,724,000228,635,000274,576,000324,312,000357,398,000380,240,000398,557,000438,754,000451,168,000493,647,000
Net income
111m
+21.17%
23,273,00022,772,00022,149,00019,615,00018,161,00020,002,00014,181,00019,518,00022,605,00025,334,00030,361,00036,591,00042,221,00051,592,00063,962,00072,549,00082,390,00089,496,00091,902,000111,360,000
CFO
115m
+14.36%
19,930,00013,044,00034,308,00016,946,00015,238,00019,975,00023,872,00031,647,00032,259,00040,912,00049,625,00041,727,00059,336,00067,585,00078,489,00079,645,000106,788,000100,969,000115,468,000
Dividend
Jul 04, 20240.116 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. It also exports its products. Faes Farma, S.A. was founded in 1933 and is headquartered in Leioa, Spain.
IPO date
Mar 25, 1994
Employees
1,764
Domiciled in
ES
Incorporated in
ES

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT